Compare ASTRAZENECA PHARMA with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PANACEA BIOTECH - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PANACEA BIOTECH ASTRAZENECA PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 73.6 12.2 602.1% View Chart
P/BV x 20.7 2.9 705.9% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
PANACEA BIOTECH
Mar-18
ASTRAZENECA PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,278364 351.1%   
Low Rs883129 683.7%   
Sales per share (Unadj.) Rs228.496.8 236.0%  
Earnings per share (Unadj.) Rs10.4-12.4 -83.5%  
Cash flow per share (Unadj.) Rs16.3-2.9 -570.1%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.850.4 196.0%  
Shares outstanding (eoy) m25.0061.25 40.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.72.5 185.7%   
Avg P/E ratio x104.2-19.9 -524.6%  
P/CF ratio (eoy) x66.4-86.4 -76.9%  
Price / Book Value ratio x10.94.9 223.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,00815,101 178.8%   
No. of employees `0001.42.5 54.9%   
Total wages/salary Rs m1,5351,516 101.3%   
Avg. sales/employee Rs Th4,210.92,401.9 175.3%   
Avg. wages/employee Rs Th1,132.2614.2 184.3%   
Avg. net profit/employee Rs Th191.1-307.9 -62.0%   
INCOME DATA
Net Sales Rs m5,7105,928 96.3%  
Other income Rs m12382 148.8%   
Total revenues Rs m5,8336,010 97.0%   
Gross profit Rs m463845 54.8%  
Depreciation Rs m147585 25.2%   
Interest Rs m01,006 0.0%   
Profit before tax Rs m438-664 -66.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m02 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m17999 181.4%   
Profit after tax Rs m259-760 -34.1%  
Gross profit margin %8.114.3 56.9%  
Effective tax rate %40.8-14.9 -274.9%   
Net profit margin %4.5-12.8 -35.4%  
BALANCE SHEET DATA
Current assets Rs m3,2095,603 57.3%   
Current liabilities Rs m2,0706,910 29.9%   
Net working cap to sales %20.0-22.0 -90.5%  
Current ratio x1.60.8 191.2%  
Inventory Days Days72206 35.1%  
Debtors Days Days3584 41.7%  
Net fixed assets Rs m7909,941 8.0%   
Share capital Rs m5061 81.6%   
"Free" reserves Rs m2,4193,026 80.0%   
Net worth Rs m2,4693,087 80.0%   
Long term debt Rs m05,707 0.0%   
Total assets Rs m4,60516,076 28.6%  
Interest coverage xNM0.3-  
Debt to equity ratio x01.8 0.0%  
Sales to assets ratio x1.20.4 336.2%   
Return on assets %5.61.5 367.9%  
Return on equity %10.5-24.6 -42.6%  
Return on capital %17.73.9 452.9%  
Exports to sales %024.0 0.0%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs mNA1,424 0.0%   
Imports (cif) Rs mNA1,040 0.0%   
Fx inflow Rs m3001,600 18.7%   
Fx outflow Rs m2,0151,131 178.1%   
Net fx Rs m-1,715469 -366.1%   
CASH FLOW
From Operations Rs m881,180 7.4%  
From Investments Rs m-94553 -16.9%  
From Financial Activity Rs mNA-1,644 0.0%  
Net Cashflow Rs m-690 -6.4%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.6 50.0%  
FIIs % 15.7 1.3 1,207.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 23.6 38.6%  
Shareholders   12,856 10,259 125.3%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  PLETHICO PHARMA  DR. REDDYS LAB  GSK PHARMA  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS